tirzepatide obstructive sleep apnea fda approval 2024 approves weight-loss drug Zepbound to treat FDA approves new sleep apnea
Description
The cardiovascular safety and efficacy of tirzepatide in adults with T2D has been assessed in a large phase 3 clinical trial (SURPASS-CVOT) (Table 1) [88]
Tirzepatide Activates both GIP and GLP-1 receptors Targets two metabolic pathways Supports appetite regulation and metabolic function Classified as a dual receptor agonist Semaglutide Activates GLP-1 receptors only Targets a single metabolic pathway Supports appetite regulation and blood sugar control Classified as a GLP-1 receptor agonist Both medications are peptides, but tirzepatides dual-receptor activity makes its mechanism of action distinct
Risks of compounded tirzepatide include dosing errors, contamination or impurities, and unapproved ingredients or formulations
Endocrine Society abstract
If prescribed, your clinician sends the tirzepatide prescription electronically to your selected pharmacy
Durante a avaliao, o profissional ir analisar o histrico de sade, os exames laboratoriais e o estilo de vida do paciente
